Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial

Annals of Surgery

Volumn 230, Issue 4, 1999, Pages 453-465

  Morton, Donald L ^a   Thompson, John F ^b   Essner, Richard ^a   Elashoff, Robert ^a   Stern, Stacey L ^a   Nieweg, Omgo E ^c   Roses, Daniel F ^d   Karakousis, Constantine P ^e   Mozzillo, Nicola ^f   Reintgen, Douglas ^g   Wang, He Jing ^h   Glass, Edwin C ^a   Cochran, Alistair J ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b MELANOMA INSTITUTE AUSTRALIA   (Australia)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d NEW YORK UNIVERSITY   (United States)

^e MILLARD FILLMORE HOSPITAL   (United States)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CANCER STAGING; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CLINICAL COMPETENCE; FEMALE; HUMANS; INCIDENCE; INTRAOPERATIVE CARE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SKIN NEOPLASMS;

EID: 0033497863     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199910000-00001     Document Type: Conference Paper

References (64)

1. Snow H. Melanotic cancerous disease. Lancet 1892; 2:872.
2. Morton DL, Wanek L, Nizze JA, et al. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 1991; 214:491-499.
3. Balch CM, Soong SJ, Murad TM. et al. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 1981; 193:377-388.
4. Milton GW, Shaw HM, McCarthy WH, et al. Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1,319 patients. Br J Surg 1982; 69:108-111.
5. Sim FH, Taylor WF, Ivins JC, et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Cancer 1978; 41:948-956.
6. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med 1977; 297:627-630.
7. Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982; 49:2420-2430.
8. Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1-to 4-mm-thick melanomas for patients 60 years of age and younger. Ann Surg 1996; 224:255-263.
9. Urist MM, Maddox WA, Kennedy JE, Balch CM. Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients. Cancer 1983; 51:2152-2156.
10. Essner R, Conforti A, Kelley MC. et al. Cost-conscious management of the inguinal nodes in early-stage melanoma. Melanoma Res 1997; 7(suppl 1):S29.
11. Cochran AJ, Wen DR, Motion DL. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. An immunohistological study. Am J Surg Pathol 1988; 12:612-618.
12. Robinson DS, Sample WF, Fee HJ, et al. Regional lymphatic drainage in primary malignant melanoma of the trunk determined by colloidal gold scanning. Surg Forum 1977; 28:147-148.
13. Wong JH, Cagle LA, Morton DL. Lymphatic drainage of skin to a sentinel lymph node in a feline model. Ann Surg 1991; 214:637-641.
14. Morton D, Cagle L, Wong J, et al. Intraoperative lymphatic mapping and selective lymphadenectomy: technical details of a new procedure for clinical stage I melanoma. Presented at the Annual Meeting of the Society of Surgical Oncology. Washington DC, 1990.
15. Gaynor R, Herschman HR, Irie R, et al. S-100 protein: a marker for human malignant melanomas? Lancet 1981; 1:869-871.
16. Cochran AJ, Wen DR, Herschman HR, Gaynor RB. Detection of S-100 protein as an aid to the identification of melanocytic tumors. Int J Cancer 1982; 30:295-297.
17. Cochran AJ, Wen DR, Herschman HR. Occult melanoma in lymph nodes detected by antiserum to S-100 protein. Int J Cancer 1984; 34:159-163.
18. Chen ZL, Perez S, Holmes EC, et al. Frequency and distribution of occult micrometastases in lymph nodes of patients with non-small cell lung carcinoma. J Natl Cancer Inst 1993; 85:493-498.
19. Callery C, Cochran AJ, Roe DJ, et al. Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes. Ann Surg 1982; 196:69-75.
20. Cochran AJ, Lana AM, Wen DR. Histomorphometry in the assessment of prognosis in stage II malignant melanoma. Am J Surg Pathol 1989; 13:600-604.
21. Cochran AJ, Pihl E, Wen DR, et al. Zoned immune suppression of lymph nodes draining malignant melanoma: histologic and immunohistologic studies. J Natl Cancer Inst 1987; 78:399-405.
22. Hoon DS, Korn EL, Cochran AJ. Variations in functional immunocompetence of individual tumor-draining lymph nodes in humans. Cancer Res 1987; 47:1740-1744.
23. Wen DR, Hoon DS, Chang C, Cochran AJ. Variations in lymphokine generation by individual lymph nodes draining human malignant tumors. Cancer Immunol Immunother 1989; 30:277-282.
24. Farzad Z, McBride WH, Ogbechi H, et al. Lymphocytes from lymph nodes at different distances from human melanoma vary in their capacity to inhibit/enhance tumor cell growth in vitro. Melanoma Res 1997; 7(suppl 2):S59-S65.
25. Hoon DS, Jung T, Naungayan J, et al. Modulation of human macrophage functions by gangliosides. Immunol Lett 1989; 20:269-276.
26. Cochran AJ, Wen DR, Farzad Z, et al. Immunosuppression by melanoma cells as a factor in the generation of metastatic disease. Anticancer Res 1989; 9:859-864.
27. Hoon DS, Bowker R, Cochran AJ. Suppressor cell activity in breast cancer-draining lymph nodes. Surg Res Commun 1990; 9:167-176.
28. Hoon DS, Bowker R, Cochran AJ. Suppressor cell activity in melanoma-draining lymph nodes. Cancer Res 1987; 47:1529-1533.
29. Mortem DL, Wen DR. Wong JH, et al. Technical details of intraoperative lymphatic mapping for early-stage melanoma. Arch Surg 1992; 127:392-399.
30. Mortem DL, Wen DR, Foshag LJ, et al. Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck, J Clin Oncol 1993; 11:1751-1756.
31. Morton DL. Sentinel lymphadenectomy for patients with clinical stage I melanoma. J Surg Oncol 1997; 66:267-269.
32. Bostick P, Essner R, Sarantou T, et al. Intraoperative lymphatic mapping for early-stage melanoma of the head and neck. Am J Surg 1997; 174:536-539.
33. Thompson JF, McCarthy WH, Bosch CM, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995; 5:255-260.
34. Reintgen D, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg 1994; 220:759-767.
35. Glass EC, Essner R, Morton DL. Kinetics of three lymphoscintigraphic agents in patients with cutaneous melanoma. J Nucl Med 1998; 39:1185-1190.
36. Kelley MC, Ollila DW, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for melanoma. Semin Surg Oncol 1998; 14:283-290.
37. Essner R. The role of lymphoscintigraphy and sentinel node mapping in assessing patient risk in melanoma. Semin Oncol 1997; 24:S8-10.
38. Essner R, Foshag L, Morton DL. Intraoperative radiolymphoscintigraphy: a useful adjuvant to intraoperative lymphatic mapping and selective lymphadenectomy in patients with clinical stage I melanoma. Presented at the Annual Meeting of the Society of Surgical Oncology, March 1994, Houston, TX.
39. Bostick P, Essner R, Glass E, et al. Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. Arch Surg 1999; 134:43-49.
40. Albertini JJ, Cruse CW, Rapaport D, et al. Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 1996; 223:217-224.
41. Krag DN, Meijer SJ, Weaver DL, et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg 1995; 130:654-658.
42. Pijpers R, Collet GJ, Meijer S, et al. The impact of dynamic lymphoscintigraphy and gamma probe guidance on sentinel node biopsy in melanoma. Eur J Nucl Med 1995; 22:1238-1241.
43. Thompson JF, Niewind P, Uren RF, et al. Single-dose isotope injection for both preoperative lymphoscintigraphy and intraoperative sentinel lymph node identification in melanoma patients. Melanoma Res 1997; 7:500-506.
44. Cochran AJ, Lu HF, Li PX, et al. S-100 protein remains a practical marker for melanocytic and other tumours. Melanoma Res 1993; 3:325-330.
45. Morton DL. Intraoperative lymphatic mapping and sentinel lymphadenectomy: community standard care or clinical investigation? Cancer J Sci Am 1997; 3:328-330.
46. Morton DL, Giuliano AE, Reintgen DS, et al. Symposium: Lymphatic mapping and sentinel node biopsy in patients with breast cancer and melanoma. Contemp Surg 1998; 53:281-298 (part 1) and 353-361 (part 2).
47. Bilchik AJ, Giuliano A, Essner R, et al. Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms. Cancer J Sci Am 1998; 4:351-358.
48. Albertini JJ. Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276:1818-1822.
49. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17:976-983.
50. Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220: 391-398.
51. Morton DL, Bostick PJ. Will the true sentinel node please stand? [editorial]. Ann Surg Oncol 1999; 6:12-14.
52. Morton D, Wen D, Cochran A. Management of early-stage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy. Surg Oncol Clin North Am 1992; 1:247-259.
53. Shivers SC, Wang X, Li W, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998; 280:1410-1415.
54. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16:2253-2260.
55. O'Brien CJ, Uren RF, Thompson JF, et al. Prediction of potential metastatic sites in cutaneous head and neck melanoma using lymphoscintigraphy. Am J Surg 1995; 170:461-466.
56. Mudun A, Murray DR, Herda SC, et al. Early-stage melanoma: lymphoscintigraphy, reproducibility of sentinel node detection, and effectiveness of the intraoperative gamma probe. Radiology 1996; 199: 171-175.
57. Thompson JF, Uren RF, Shaw HM, et al. The location of sentinel lymph nodes in patients with cutaneous melanoma: new insights into lymphatic anatomy. J Am Coll Surg (in press).
58. Uren RF, Thompson JF, Howman-Giles RB. Lymphatic drainage of the skin and breast: locating the sentinel nodes. Amsterdam: Harwood Academic Publishers; 1999.
59. Ross MI, Reinigen D, Balch CM. Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early-stage melanoma. Semin Surg Oncol 1993; 9:219-223.
60. Leong SP, Steinmetz I, Habib FA, et al. Optimal selective sentinel lymph node dissection in primary malignant melanoma. Arch Surg 1997; 132:666-672.
61. Bachter D, Balda BR, Vogt H, et al. Primary therapy of malignant melanomas: sentinel lymphadenectomy. Int J Dermatol 1998; 37:278-282.
62. van der Veen H, Hoekstra OS, Paul MA, et al. Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy. Br J Surg 1994; 81:1769-1770.
63. Reintgen D. Lymphatic mapping and sentinel node harvest for malignant melanoma. J Surg Oncol 1997; 66:277-281.
64. Alex JC, Weaver DL, Fairbank JT, et al. Gamma probe-guided lymph node localization in malignant melanoma. Surg Oncol 1993; 2:303-308.